Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dynavax Technologies has expanded its worldwide strategic alliance with GlaxoSmithKline (GSK) on toll-like receptor (TLR) inhibitors and will receive a $3m milestone payment from GSK, with the addition of new target, TLR8.
Subscribe to our email newsletter
Dynavax expects to receive nearly $200m in milestone payments over the term of the alliance.
Dynavax and GSK will focus on the development of a TLR8 inhibitor to treat multiple autoimmune and inflammatory diseases.
TLR inhibitors are oligonucleotides, called immunoregulatory sequences (IRS), which cause the inhibition of TLR-induced inflammatory response linked to autoimmune and inflammatory diseases.